264 related articles for article (PubMed ID: 25042790)
21. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
[TBL] [Abstract][Full Text] [Related]
22. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
Hughes CF; Newland K; McCormack C; Lade S; Prince HM
Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
[TBL] [Abstract][Full Text] [Related]
23. Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome.
Martinez XU; Di Raimondo C; Abdulla FR; Zain J; Rosen ST; Querfeld C
Best Pract Res Clin Haematol; 2019 Sep; 32(3):239-252. PubMed ID: 31585624
[TBL] [Abstract][Full Text] [Related]
24. Mycosis fungoides and sezary syndrome: an update.
Kim EJ; Lin J; Junkins-Hopkins JM; Vittorio CC; Rook AH
Curr Oncol Rep; 2006 Sep; 8(5):376-86. PubMed ID: 16901399
[TBL] [Abstract][Full Text] [Related]
25. Staging and management of cutaneous T-cell lymphoma.
Scarisbrick JJ
Clin Exp Dermatol; 2006 Mar; 31(2):181-6. PubMed ID: 16487086
[TBL] [Abstract][Full Text] [Related]
26. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
27. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Wong HK; Mishra A; Hake T; Porcu P
Br J Haematol; 2011 Oct; 155(2):150-66. PubMed ID: 21883142
[TBL] [Abstract][Full Text] [Related]
28. Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach.
Horwitz SM; Olsen EA; Duvic M; Porcu P; Kim YH
J Natl Compr Canc Netw; 2008 Apr; 6(4):436-42. PubMed ID: 18433609
[TBL] [Abstract][Full Text] [Related]
29. How I treat mycosis fungoides and Sézary syndrome.
Prince HM; Whittaker S; Hoppe RT
Blood; 2009 Nov; 114(20):4337-53. PubMed ID: 19696197
[TBL] [Abstract][Full Text] [Related]
30. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.
Berg S; Villasenor-Park J; Haun P; Kim EJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):234-243. PubMed ID: 28540671
[TBL] [Abstract][Full Text] [Related]
31. Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
Bhabha FK; McCormack C; Wells J; Campbell BA; Newland K; Lade S; Buelens O; Joske D; Shortt J; Mapp S; Radeski D; Hertzberg M; Khot A; Van Der Weyden C; Khoo C; Hawkes E; Prince HM
Australas J Dermatol; 2021 Feb; 62(1):e8-e18. PubMed ID: 33368169
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
33. Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update.
Parker SR; Bethaney JV
G Ital Dermatol Venereol; 2009 Aug; 144(4):467-85. PubMed ID: 19755952
[TBL] [Abstract][Full Text] [Related]
34. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.
Stevens SR; Baron ED; Masten S; Cooper KD
Arch Dermatol; 2002 Oct; 138(10):1347-50. PubMed ID: 12374541
[TBL] [Abstract][Full Text] [Related]
35. Mycosis fungoides and Sézary syndrome.
Jonak C; Tittes J; Brunner PM; Guenova E
J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
[TBL] [Abstract][Full Text] [Related]
36. A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome.
Thomas BR; Whittaker S
Skin Therapy Lett; 2012 Dec; 17(10):5-9. PubMed ID: 23223768
[TBL] [Abstract][Full Text] [Related]
37. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).
Olsen EA; Rook AH; Zic J; Kim Y; Porcu P; Querfeld C; Wood G; Demierre MF; Pittelkow M; Wilson LD; Pinter-Brown L; Advani R; Parker S; Kim EJ; Junkins-Hopkins JM; Foss F; Cacchio P; Duvic M
J Am Acad Dermatol; 2011 Feb; 64(2):352-404. PubMed ID: 21145619
[TBL] [Abstract][Full Text] [Related]
38. Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome.
Prince HM; Querfeld C
Best Pract Res Clin Haematol; 2018 Sep; 31(3):322-335. PubMed ID: 30213403
[TBL] [Abstract][Full Text] [Related]
39. How I treat mycosis fungoides and Sézary syndrome.
Whittaker S; Hoppe R; Prince HM
Blood; 2016 Jun; 127(25):3142-53. PubMed ID: 27151889
[TBL] [Abstract][Full Text] [Related]
40. Mycosis fungoides and the Sézary syndrome: a review of pathogenesis, diagnosis, and therapy.
Kuzel TM; Roenigk HH; Rosen ST
J Clin Oncol; 1991 Jul; 9(7):1298-313. PubMed ID: 2045869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
